Chemokine Receptors in Allergy, Inflammation, and Infectious Disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/7355_2014_39
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)

  2014cited by this paper
• Internalization of CCR4 and Inhibition of Chemotaxis by K777, a Potent and Selective CCR4 Antagonist

  2013cited by this paper
• Identification of human CCR8 as a CCL18 receptor

  2013cited by this paper
• Eosinophils in Health and Disease

  2013cited by this paper
• Antagonism of chemokine receptor CCR8 is ineffective in a primate model of asthma

  2013cited by this paper
• Type 2 innate lymphoid cells control eosinophil homeostasis

  2013cited by this paper
• The discovery of BMS-457, a potent and selective CCR1 antagonist.

  2013cited by this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

  2013cited by this paper
• CCL26/eotaxin‐3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin‐1 and CCL24/eotaxin‐2

  2013cited by this paper
• Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice

  2013cited by this paper
• The cost burden of multiple sclerosis in the United States: a systematic review of the literature

  2013cited by this paper
• Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers.

  2013cited by this paper
• Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex

  2013cited by this paper
• Suppression of laser-induced choroidal neovascularization by a CCR3 antagonist.

  2013cited by this paper
• Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.

  2012cited by this paper
• Asthma phenotypes: the evolution from clinical to molecular approaches

  2012cited by this paper
• Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration.

  2012cited by this paper
• Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

  2012cited by this paper
• Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation.

  2012cited by this paper
• Overcoming hurdles in developing successful drugs targeting chemokine receptors

  2011cited by this paper
• Targeting chemokine receptors in allergic disease.

  2011cited by this paper
• The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

  2011cited by this paper
• Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose

  2011cited by this paper
• AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome

  2011cited by this paper
• The aging systemic milieu negatively regulates neurogenesis and cognitive function

  2011cited by this paper
• CCR3 and Choroidal Neovascularization

  2011cited by this paper
• Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration.

  2011cited by this paper
• TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge

  2011cited by this paper
• The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

  2011cited by this paper
• Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.

  2011cited by this paper
• Small molecule antagonists of CCR8 inhibit eosinophil and T cell migration.

  2011cited by this paper
• Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)*

  2011cited by this paper
• Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling.

  2011cited by this paper
• Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ TH2 cells

  2011cited by this paper
• Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis

  2011cited by this paper
• Expression of CCR8 is increased in asthma

  2010cited by this paper
• Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis

  2010cited by this paper
• A novel CC-chemokine receptor 3 antagonist, Ki19003, inhibits airway eosinophilia and subepithelial/peribronchial fibrosis induced by repeated antigen challenge in mice.

  2010cited by this paper
• Is there a role for CCR8 in the pathogenesis of asthma?

  2010cited by this paper
• T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

  2010cited by this paper
• Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.

  2010cited by this paper
• CC Chemokine Receptor 4 (CCR4) in human allergen‐induced late nasal responses

  2010cited by this paper
• Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.

  2010cited by this paper
• A novel CC chemokine receptor 4 antagonist RS-1269 inhibits ovalbumin-induced ear swelling and lipopolysaccharide-induced endotoxic shock in mice.

  2010cited by this paper
• Fingolimod is a potential novel therapy for multiple sclerosis

  2010cited by this paper
• CCR1 antagonists: what have we learned from clinical trials.

  2010cited by this paper
• Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists

  2010cited by this paper
• RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs.

  2010cited by this paper
• Collagen V-induced nasal tolerance downregulates pulmonary collagen mRNA gene and TGF-beta expression in experimental systemic sclerosis

  2010cited by this paper
• CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial

  2010cited by this paper
• Chemokine receptor antagonists: overcoming developmental hurdles

  2009cited by this paper
• MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.

  2009cited by this paper
• Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice.

  2009cited by this paper
• Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC‐derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation

  2009cited by this paper
• CCR3 is a therapeutic and diagnostic target for neovascular age-related macular degeneration

  2009cited by this paper
• Inhibitory Effect of the New Orally Active CCR4 Antagonist K327 on CCR4+CD4+ T Cell Migration into the Lung of Mice with Ovalbumin-Induced Lung Allergic Inflammation

  2008cited by this paper
• Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases

  2008cited by this paper
• Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.

  2008cited by this paper
• Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

  2008cited by this paper
• From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.

  2008cited by this paper
• Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.

  2008cited by this paper
• Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.

  2008cited by this paper
• An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5

  2008cited by this paper
• Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor Activation*

  2007cited by this paper
• Chapter 14 Advances in the Discovery of CC Chemokine Receptor 2 Antagonists

  2007cited by this paper
• Natalizumab for multiple sclerosis.

  2007cited by this paper
• Discovery of small molecule CXCR4 antagonists.

  2007cited by this paper
• Mechanisms of leukocyte trafficking in allergic diseases: insights into new therapies targeting chemokines and chemokine receptors

  2007cited by this paper
• MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

  2007cited by this paper
• Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

  2007cited by this paper
• CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.

  2007cited by this paper
• 11th Annual Inflammatory and Immune Diseases Drug Discovery and Development Summit

  2007cited by this paper
• The Human Specific CCR1 Antagonist CP-481,715 Inhibits Cell Infiltration and Inflammatory Responses in Human CCR1 Transgenic Mice

  2006cited by this paper
• Chemokines in rheumatic diseases.

  2006cited by this paper
• The Discovery of CCR5 Receptor Antagonists for the Treatment of HIV Infection: Hit‐to‐Lead Studies

  2006cited by this paper
• CC chemokine ligand 1 is released into the airways of atopic asthmatics

  2006cited by this paper
• A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

  2006cited by this paper
• Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.

  2006cited by this paper
• The many roles of chemokines and chemokine receptors in inflammation.

  2006cited by this paper
• Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo

  2006cited by this paper
• Blockade of chemokine signaling in patients with multiple sclerosis

  2006cited by this paper
• Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.

  2006cited by this paper
• In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031.

  2006cited by this paper
• A Novel, Selective, and Orally Available Antagonist for CC Chemokine Receptor 3

  2006cited by this paper
• Involvement of CCL18 in Allergic Asthma1

  2006cited by this paper
• Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction.

  2005cited by this paper
• Chemokine receptor expression in rat adjuvant-induced arthritis.

  2005cited by this paper
• The Eotaxin Chemokines and CCR3 Are Fundamental Regulators of Allergen-Induced Pulmonary Eosinophilia1

  2005cited by this paper
• Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis

  2005cited by this paper
• Identification of chemokine receptor CCR4 antagonist.

  2005cited by this paper
• Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

  2005cited by this paper
• Site-directed Mutagenesis of CC Chemokine Receptor 1 Reveals the Mechanism of Action of UCB 35625, a Small Molecule Chemokine Receptor Antagonist*

  2005cited by this paper
• Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5.

  2005cited by this paper
• IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

  2005cited by this paper
• Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.

  2005cited by this paper
• Thymic Stromal Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with Expression of Th2-Attracting Chemokines and Disease Severity1

  2005cited by this paper
• The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists.

  2005cited by this paper
• The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor

  2005cited by this paper
• Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.

  2005cited by this paper
• Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

  2004cited by this paper

• Functional genetic encoding of sulfotyrosine in mammalian cells

  2020cites this paper
• VU Research Portal In silico Medicinal

  2015cites this paper